Notably, a new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have been demonstrated to directly improve endothelial function [25]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.